BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Bell AW. Personalized Medicine for Liver Disease: From Molecular Mechanisms to Potential Targeted Therapies. JPM 2022;12:663. [DOI: 10.3390/jpm12050663] [Reference Citation Analysis]
2 Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;:101816. [PMID: 34607067 DOI: 10.1016/j.clinre.2021.101816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang S, Jiu Lüe H, Zhao J. Study on Syndrome Intervention of Nonalcoholic Fatty Liver Disease from the Perspective of Deficiency and Excess. J Healthc Eng 2021;2021:9928160. [PMID: 34567490 DOI: 10.1155/2021/9928160] [Reference Citation Analysis]
4 Yabiku K. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence. Front Endocrinol (Lausanne) 2021;12:768850. [PMID: 34950104 DOI: 10.3389/fendo.2021.768850] [Reference Citation Analysis]